Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
CTNMthis companyContineum Therapeutics, Inc.	$10.02	-5.27×	1.21×	0×	-3.68×	-74.9%	0.0%	0.0%	0.0%	-23.0%	-25.3%	-17.5%	0.03×	0.99×	0×	27.5×	0.0%	2	16.76	2	C+
ANROAlto Neuroscience, Inc.	$28.98	-8.13×	3.4×	0×	-5.68×	-73.1%	0.0%	0.0%	0.0%	-41.8%	-38.2%	-10.1%	0.03×	2.86×	-26.88×	15.69×	0.0%	2	13.38	2	C+
LBRXLB Pharmaceuticals Inc Common Stock	$43.40	-22.26×	1.87×	0×	-12.72×	-75.2%	0.0%	0.0%	0.0%	-8.4%	-9.9%	-6.3%	0.01×	9.91×	0×	41.44×	0.0%	2	25.27	2	C+
MPLTMapLight Therapeutics, Inc.	$7.37	-4.8×	1.69×	0×	-4.56×	-86.3%	0.0%	0.0%	0.0%	-35.2%	-36.4%	-17.9%	0.01×	0.25×	0×	20.01×	0.0%	2	5.7	2	C
NMRANeumora Therapeutics, Inc. Common Stock	$0.53	-1.23×	2.82×	0×	-0.47×	121.4%	0.0%	0.0%	0.0%	-228.1%	-151.8%	-70.6%	0×	0.78×	-74.92×	5.87×	0.0%	2	-18.15	2	C+
RAPPRapport Therapeutics, Inc. Common Stock	$24.84	-10.61×	2.94×	0×	-11.16×	-96.8%	0.0%	0.0%	0.0%	-23.0%	-25.2%	-6.2%	0.02×	0.33×	0×	26.17×	0.0%	2	19.18	2	C
Peer median	—	-8.13×	2.82×	0×	-5.68×	-75.2%	0.0%	0.0%	0.0%	-35.2%	-36.4%	-10.1%	0.01×	0.78×	0×	20.01×	0.0%	2	13.38	2	—